Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

Also called NCT02517866

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 380 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02517866
  • WHO UTN U1111-1156-8501
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02517866. Allocation not applicable; no masking; primary purpose treatment. Start 2015-07-13 (actual); primary completion 2016-11-15 (actual). Results posted on 2019-03-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Condition
Essential Hypertension
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Azilsartan Medoxomil
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02517866
Content hash
319a5d0c4cf4f9297fd3ea4e38d7dce3867135211b9aaee0969f61b2d41b649a